Interpace Biosciences Analysis
Interpace Biosciences is undervalued with Real Value of 0.0 and Hype Value of 0.0. The main objective of Interpace Biosciences otc analysis is to determine its intrinsic value, which is an estimate of what Interpace Biosciences is worth, separate from its market price. There are two main types of Interpace Biosciences' stock analysis: fundamental analysis and technical analysis.
The Interpace Biosciences otc stock is traded in the USA on OTCQX Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Interpace Biosciences' ongoing operational relationships across important fundamental and technical indicators.
Interpace |
Interpace OTC Stock Analysis Notes
About 28.0% of the company shares are held by company insiders. The company recorded a loss per share of 3.12. Interpace Biosciences last dividend was issued on the 15th of January 2020. The entity had 1:10 split on the 15th of January 2020. Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey. Interpace Diag operates under Diagnostics Research classification in the United States and is traded on OTC Exchange. It employs 147 people.The quote for Interpace Biosciences is listed on Over The Counter exchange (i.e., OTC), and the entity is not required to meet listing requirements such as those found on the Nasdaq, NYSE, or AMEX exchanges. To learn more about Interpace Biosciences call Thomas Burnell at 855 776-6419 or check out www.interpacediagnostics.com.Interpace Biosciences Investment Alerts
| Interpace Biosciences is not yet fully synchronised with the market data | |
| Interpace Biosciences has some characteristics of a very speculative penny stock | |
| Interpace Biosciences has a very high chance of going through financial distress in the upcoming years | |
| Interpace Biosciences currently holds 9.44 M in liabilities with Debt to Equity (D/E) ratio of 6.55, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Interpace Biosciences has a current ratio of 0.6, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Interpace Biosciences until it has trouble settling it off, either with new capital or with free cash flow. So, Interpace Biosciences' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Interpace Biosciences sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Interpace to invest in growth at high rates of return. When we think about Interpace Biosciences' use of debt, we should always consider it together with cash and equity. | |
| The entity reported the previous year's revenue of 41.31 M. Net Loss for the year was (14.94 M) with profit before overhead, payroll, taxes, and interest of 17.95 M. | |
| Interpace Biosciences currently holds about 1.86 M in cash with (8.72 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.44. | |
| Roughly 28.0% of Interpace Biosciences shares are held by company insiders |
Interpace Biosciences Upcoming and Recent Events
Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Interpace Biosciences previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 25th of March 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
Interpace Market Capitalization
The company currently falls under 'Nano-Cap' category with a current market capitalization of 5.16 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Interpace Biosciences's market, we take the total number of its shares issued and multiply it by Interpace Biosciences's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.Interpace Profitablity
Interpace Biosciences' profitability indicators refer to fundamental financial ratios that showcase Interpace Biosciences' ability to generate income relative to its revenue or operating costs. If, let's say, Interpace Biosciences is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Interpace Biosciences' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Interpace Biosciences' profitability requires more research than a typical breakdown of Interpace Biosciences' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Profit Margin (PM) of (0.59) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.28) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.28. Interpace Biosciences Outstanding Bonds
Interpace Biosciences issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Interpace Biosciences uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Interpace bonds can be classified according to their maturity, which is the date when Interpace Biosciences has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| INTERPUBLIC GROUP INC Corp BondUS460690BP43 | View | |
| INTERPUBLIC GROUP INC Corp BondUS460690BQ26 | View | |
| US460690BR09 Corp BondUS460690BR09 | View | |
| IPG 3375 01 MAR 41 Corp BondUS460690BS81 | View |
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our otc stock analysis tools, you can find out how much better you can do when adding Interpace Biosciences to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Pair Correlation Now
Pair CorrelationCompare performance and examine fundamental relationship between any two equity instruments |
| All Next | Launch Module |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in interest. You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Other Consideration for investing in Interpace OTC Stock
If you are still planning to invest in Interpace Biosciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Interpace Biosciences' history and understand the potential risks before investing.
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities |